(Q33664087)

28 July 2017

1 reference

title

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe? (English)

1 reference

28 July 2017

Lars L Gustafsson

17

0 references

William H Shrank

2

object named as

William Shrank

1 reference

28 July 2017

3

Bjorn Wettermark

1 reference

28 July 2017

9

Ott Laius

1 reference

28 July 2017

11

Catherine Sermet

1 reference

28 July 2017

16

Corinne Zara

1 reference

28 July 2017

1

Brian Godman

1 reference

28 July 2017

8

Marija Kalaba

1 reference

28 July 2017

6

Thomas Burkhardt

1 reference

28 July 2017

10

Roberta Joppi

1 reference

28 July 2017

14

F Cankat Tulunay

1 reference

28 July 2017

15

Kamila Wendykowska

1 reference

28 July 2017

Morten Andersen

4

1 reference

28 July 2017

Iain Bishop

5

1 reference

28 July 2017

Kristina Garuolienè

7

1 reference

28 July 2017

Ulrich Schwabe

12

1 reference

28 July 2017

Inês Teixeira

13

1 reference

28 July 2017

publication date

5 August 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

3

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

2470-2494

1 reference

Creative Commons Attribution 4.0 International

28 July 2017

copyright license

start time

5 August 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

The Portuguese generic medicines market: a policy analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Forecasting drug utilization and expenditure in a metropolitan health region

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Physician and patient characteristics associated with prescriptions and costs of drugs in the Lazio region of Italy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Developing competitive and sustainable Polish generic medicines market

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Health economics of market access for biopharmaceuticals and biosimilars

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Patients' perceptions of generic medications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Balancing Big Pharma's books

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Pharmaceutical policies: effects of financial incentives for prescribers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Increasing generic drug use in Medicare Part D: the role of government

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Economic aspects of the new Spanish laws on pharmaceutical preparations.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Evaluation of an interchangeability switch in patients treated with clozapine: A retrospective review.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Variations and increase in use of statins across Europe: data from administrative databases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

21 June 2018

1 reference

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

21 January 2018

1 reference

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation

21 January 2018

1 reference

Clinical equivalence of generic clozapine

21 January 2018

1 reference

Generic clozapine: outcomes after switching formulations.

21 January 2018

1 reference

Generic olanzapine: health authority opportunity or nightmare?

21 January 2018

1 reference

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

21 January 2018

1 reference

Potential savings without compromising the quality of care

21 January 2018

1 reference

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

21 January 2018

1 reference

21 January 2018

1 reference

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries

21 January 2018

1 reference

Current national initiatives about drug policies and cost control in Europe: the Italy example.

21 January 2018

1 reference

Healthcare policies over the last 20 years: reforms and counter-reforms

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4033935

New drugs for old: disinvestment and NICE

30 October 2018

1 reference

International comparison of generic medicine prices

21 January 2018

1 reference

12 December 2020

Generics: what is the role of registration authorities

1 reference

12 December 2020

Generic medicine pricing in Europe: current issues and future perspective

1 reference

12 December 2020

Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries

1 reference

12 December 2020

Trends in generic prescribing and dispensing in Europe

1 reference

12 December 2020

People's views on the level of agreement of generic medicines for different illnesses

1 reference

12 December 2020

Indonesian doctors are told to prescribe generics to reduce health costs

1 reference

12 December 2020

Generic medicines: Greek physicians' perceptions and prescribing practices

1 reference

12 December 2020

Patients' attitudes towards and experiences of generic drug substitution in Norway

1 reference

12 December 2020

Do generics offer significant savings to the UK National Health Service?

1 reference

12 December 2020

Off-patent drugs in Italy. A short-sighted view?

1 reference

12 December 2020

Interchangeability of off-patent medicines: a pharmacoeconomic perspective

1 reference

12 December 2020

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting

1 reference

12 December 2020

Increasing psychosis in a patient switched from clozaril to generic clozapine

1 reference

12 December 2020

The selection of essential drugs: report of a WHO expert committee

1 reference

12 December 2020

What do primary care patients think about generic drugs?

1 reference

12 December 2020

Tier 4 drugs and the fraying of the social compact

1 reference

12 December 2020

Pharmaceutical policy in Italy: towards a structural change?

1 reference

12 December 2020

Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland

1 reference

12 December 2020

[Policies encouraging price competition in the generic drug market: Lessons from the European experience]

1 reference

12 December 2020

Assessing lay beliefs about generic medicines: Development of the generic medicines scale

1 reference

12 December 2020

Identifiers

DOI

10.3390/PH3082470

1 reference

28 July 2017

1 reference

28 July 2017

1 reference